Bogdana Schmidt, MD
Urology · Salt Lake City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · University of Utah Adult Services · 1,758 clinicians in this group
Hospitals listed: Memorial Hospital Sweetwater County · University of Utah Hospital and Clinics. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Schmidt’s office at (801) 581-8793 to ask if they take your plan before you enroll.
California Medical Board record
Licence A133342 · Delinquent
Licence status: Delinquent · since 2014 · expires 2022-04-30 · University of California San Francisco School of Medicine.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Memorial Hospital Sweetwater CountyRock Springs, WYCritical Access Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPatients rate it 4 of 5 · 63% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
- University of Utah Hospital and ClinicsSalt Lake City, UTAcute Care Hospital · Government - State · Has an emergency department · Birthing-friendlyPart of University of Utah Hospitals and Clinics, which runs 2 hospitalsHome of Huntsman Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.603, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.55, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.518, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.595, Oct 2024 – Sep 2025Better than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 8.8 (7.3 to 10.3) · 1,119 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Memorial Hospital Sweetwater County
| Death rate for COPD patientsComplications and deaths | 9.7 · 49 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 108 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 324 cases | None | Jul 2024 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17.5 · 103 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -28.7 · 107 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 86 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.3 to 7.7) · 78 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9 (6.2 to 12.8) · 78 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.3 to 16.6) · 278 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 220 cases | No different | Jan 2024 – Dec 2024 |
What patients said (181 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 65% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 63% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 94% |
See every measure and the patient survey for University of Utah Hospital and Clinics
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 1 worse of 8 measures. Readmissions: 2 better, 8 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.603 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.55 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.518 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.595 | Better | Oct 2024 – Sep 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.8 (7.3 to 10.3) · 1,119 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.78 (0.03 to 1.53) · 3,231 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.6 to 1.22) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 156.56 (123.99 to 189.13) · 297 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.3 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 168 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 423 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.7 · 347 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.8 · 506 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,004 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0.02 to 0.37) · 11,361 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.08 to 0.43) · 12,089 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.06 (2.7 to 5.41) · 4,881 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.58 (0 to 3.27) · 204 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.55 (1.5 to 3.59) · 4,443 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.76 (0 to 15.4) · 212 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.49 (1.4 to 9.58) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.88 (0.63 to 3.14) · 1,317 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.5 (0.08 to 0.92) · 10,150 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.8 · 289 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.204 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.738 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.5 · 213 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 17.5 · 664 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.4 · 180 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -34.8 · 478 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -7 · 374 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 535 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.8 (4.6 to 7) · 1,119 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 310 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.2 · 113 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.9 to 15.8) · 2,684 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.2) · 2,156 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,497 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 61% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$91,573
Medicare paid this office $91,573 for 187 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 17 | $15,168 | $892 |
| New patient visit (60+ min) | 42 | $5,170 | $123 |
| Return visit (30+ min) | 40 | $4,833 | $90 |
| Return visit (30+ min) | 48 | $4,556 | $70 |
| Diagnostic exam of bladder and urethra using an endoscope | 38 | $4,401 | $55 |
See all 10 services
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 17 | $15,168 | $892 |
| New patient visit (60+ min) | 42 | $5,170 | $123 |
| Return visit (30+ min) | 40 | $4,833 | $90 |
| Return visit (30+ min) | 48 | $4,556 | $70 |
| Diagnostic exam of bladder and urethra using an endoscope | 38 | $4,401 | $55 |
| Long return visit (40+ min) | 30 | $3,384 | $97 |
| Removal of lymph nodes of both sides of pelvis using an endoscope | 12 | $3,071 | $256 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 12 | $2,894 | $223 |
| New patient visit (60+ min) | 17 | $2,769 | $163 |
| Insertion of stent in ureter using an endoscope | 12 | $1,212 | $101 |
Procedures Medicare counted
| Prostate resection | 17 | More than 74% of doctors who do this |
Who their Medicare patients are
187 Original Medicare patients in 2024. Average age 73 · Women 19% · Also on Medicaid 8% · Health risk score 1.50. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: Cancer 70% · High blood pressure 63% · Diabetes 27% · Chronic kidney disease 27% · Coronary heart disease 21% · Depression 20% · Atrial fibrillation 17% · Heart failure 14% · COPD 13%.
The office billed $482,913, Medicare allowed $118,505 and paid $91,573; for 495 services of 50 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 187 | 495 | 73 | 1.50 | $482,913 | $91,573 |
| 2023 | 157 | 361 | 73 | 1.46 | $303,631 | $60,386 |
| 2022 | 119 | 289 | 72 | 1.76 | $311,723 | $62,129 |
| 2021 | 31 | 58 | 74 | 0.97 | $48,451 | $9,292 |
| 2020 | 18 | 29 | 73 | 2.72 | $192,968 | $3,306 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| New patient visit (60+ min) | 43 | $5,639 | $131 |
| Long return visit (40+ min) | 39 | $3,880 | $97 |
| Return visit (30+ min) | 44 | $3,746 | $67 |
| Diagnostic exam of bladder and urethra using an endoscope | 28 | $2,485 | $54 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 11 | $2,219 | $202 |
| Return visit (30+ min) | 18 | $1,523 | $69 |
2022: 6 services
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 12 | $13,291 | $1,108 |
| Long return visit (40+ min) | 49 | $7,269 | $110 |
| New patient visit (60+ min) | 39 | $5,095 | $131 |
| Removal of lymph nodes of both sides of pelvis using an endoscope | 12 | $3,101 | $258 |
| Diagnostic exam of bladder and urethra using an endoscope | 18 | $1,559 | $58 |
| Return visit (30+ min) | 15 | $1,146 | $64 |
2021: 1 service
| New patient visit (60+ min) | 15 | $2,162 | $144 |
Medicaid work
$0 in 2018
Medicaid paid $0 for 56 billed services this clinician did in 2018, up to 28 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 56 | $0 |
| 2018 | 56 | 1 | 28 | $0 |
Drugs they prescribed that Part D paid
$14,531
Pharmacies billed $14,531 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
96 generic and 29 brand-name prescriptions · $14,531 in drug cost · 12 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 16 | $7,319 | $457 |
| Eliquis | 11 | $5,228 | $475 |
| Tamsulosin | 23 | $168 | $7 |
| Oxybutynin Chloride | 14 | $44 | $3 |
Year by year
| 2024 | 125 | 47 | None | 23% | $14,531 |
| 2023 | 96 | 41 | None | None | $8,335 |
| 2022 | 61 | 22 | None | None | $4,085 |
| 2019 | 52 | 24 | None | 37% | $7,195 |
| 2018 | 45 | 22 | None | 29% | $6,287 |
| 2017 | 21 | 17 | 71% (15) | None | $289 |
| 2016 | 100 | 40 | 13% (13) | None | $4,909 |
| 2015 | 157 | 61 | None | 13% | $5,484 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Methenamine Hippurate | 13 | $1,073 | $83 |
| Tamsulosin | 24 | $513 | $21 |
| Finasteride | 11 | $166 | $15 |
2022: 1 drug
| Tamsulosin | 19 | $382 | $20 |
2019: 1 drug
| Myrbetriq | 12 | $4,452 | $371 |
2017: 1 drug
| Hydrocodone-Acetaminophen | 11 | $64 | $6 |
2016: 2 drugs
| Tamsulosin | 24 | $707 | $29 |
| Finasteride | 16 | $175 | $11 |
2015: 3 drugs
| Tamsulosin | 38 | $1,261 | $33 |
| Finasteride | 25 | $371 | $15 |
| Ciprofloxacin | 27 | $87 | $3 |
Money from drug and device companies
$18,348 in 2025
| 2025 | 6 | 27 | $15,598 | $18,348 |
| 2024 | 5 | 37 | $10,050 | $16,795 |
| 2023 | 4 | 6 | None | $420 |
| 2022 | 4 | 5 | None | $312 |
| 2021 | 1 | 1 | None | $119 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ferring Pharmaceuticals | Adstiladrin | $11,534 | 11 payments
|
| Janssen Global Services | None | $3,084 | 3 payments
|
| Intuitive Surgical | Da Vinci Sp | $1,659 | 5 payments
|
| Janssen Scientific Affairs | None | $1,031 | 4 payments
|
| Janssen Biotech | Erleada | $965 | 3 payments
|
| Coloplast | Altis | $76 | 1 payment
|
See all 27 published payments
| Ferring Pharmaceuticals | Consulting · 2025-12-22 | Adstiladrin | $8,075 |
| Ferring Pharmaceuticals | Travel · 2025-12-13 | Adstiladrin | $117 |
| Ferring Pharmaceuticals | Meals · 2025-12-13 | Adstiladrin | $32 |
| Ferring Pharmaceuticals | Meals · 2025-12-13 | Adstiladrin | $39 |
| Ferring Pharmaceuticals | Meals · 2025-12-12 | Adstiladrin | $76 |
| Janssen Global Services | Meals · 2025-12-05 | None | $47 |
| Janssen Global Services | Consulting · 2025-12-05 | None | $2,538 |
| Janssen Scientific Affairs | Meals · 2025-12-04 | None | $47 |
| Ferring Pharmaceuticals | Consulting · 2025-11-14 | Adstiladrin | $2,850 |
| Ferring Pharmaceuticals | Meals · 2025-11-03 | Adstiladrin | $43 |
| Coloplast | Meals · 2025-10-14 | Altis | $76 |
| Ferring Pharmaceuticals | Meals · 2025-08-16 | Adstiladrin | $41 |
| Ferring Pharmaceuticals | Meals · 2025-04-28 | Adstiladrin | $57 |
| Janssen Scientific Affairs | Meals · 2025-04-27 | None | $150 |
| Janssen Scientific Affairs | Consulting · 2025-04-27 | None | $818 |
| Janssen Scientific Affairs | Meals · 2025-04-27 | None | $17 |
| Janssen Biotech | Consulting · 2025-04-27 | None | $818 |
| Janssen Biotech | Meals · 2025-04-25 | Erleada | $24 |
| Janssen Biotech | Meals · 2025-04-25 | Erleada | $124 |
| Ferring Pharmaceuticals | Meals · 2025-04-22 | Adstiladrin | $98 |
| Janssen Global Services | Consulting · 2025-04-16 | None | $500 |
| Intuitive Surgical | Meals · 2025-03-18 | Da Vinci Surgical System | $90 |
| Intuitive Surgical | Meals · 2025-03-18 | Da Vinci Surgical System | $3 |
| Intuitive Surgical | Meals · 2025-03-18 | Da Vinci Surgical System | $52 |
| Ferring Pharmaceuticals | Meals · 2025-02-15 | Adstiladrin | $105 |
| Intuitive Surgical | Meals · 2025-02-04 | Da Vinci Surgical System | $14 |
| Intuitive Surgical | Education · 2025-01-17 | Da Vinci Sp | $1,500 |
See earlier years (2024, 2023, 2022, 2021)
2024: $16,795
| Ferring Pharmaceuticals | Adstiladrin | $7,111 | 9 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $5,541 | 22 payments
|
| Urogen Pharma | Jelmyto | $3,937 | 3 payments
|
| Coloplast | Titan | $125 | 1 payment
|
| Boston Scientific | Lithovue | $81 | 2 payments
|
2023: $420
| Janssen Research & Development | None | $180 | 3 payments
|
| Fennec Pharmaceuticals | Pedmark | $137 | 1 payment
|
| Coloplast | Titan | $68 | 1 payment
|
| Teleflex | Urolift | $36 | 1 payment
|
2022: $312
| UroGen Pharma | Jelmyto | $150 | 1 payment
|
| Janssen Research & Development | None | $100 | 2 payments
|
| Boston Scientific | Ams 700 Cxr Rte Kit | $33 | 1 payment
|
| Myriad Genetic Laboratories | Prolaris | $29 | 1 payment
|
2021: $119
| Boston Scientific | General Kidney Stone Disease | $119 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · 2023 | Their institution | $100,169 |
| Janssen Research & Development, LLC · A Study of Tar-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (Sunrise-4) · 2025 | Their institution | $82,522 |
| Janssen Research & Development, LLC · 2024 | Their institution | $57,600 |
| Janssen Research & Development, LLC · A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of Tar-200 in Combination With Cetrelimab Versus Intravesical Bacillus Calmettegurin (Bcg) in Participants With Bcg-Nave High-Risk Non-Muscle Invasive Bladder Canc · 2024 | Their institution | $41,146 |
| Ferring Pharmaceuticals AS · Adstiladrin Early Utilization and Outcomes in the Real World Setting in the United States · 2025 | Their institution | $20,726 |
| Janssen Research & Development, LLC · A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of Tar-200 in Combination With Cetrelimab Versus Intravesical Bacillus Calmettegu?Rin (Bcg) in Participants With Bcg-Na?Ve High-Risk Non-Muscle Invasive Bladder Canc · 2023 | Their institution | $20,000 |
| Janssen Research & Development, LLC · A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of Tar-200 in Combination With Cetrelimab Versus Intravesical Bacillus Calmettegurin (Bcg) in Participants With Bcg-Nave High-Risk Non-Muscle Invasive Bladder Canc · 2025 | Their institution | $3,743 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 92.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1386987865
- Licence
- CA A133342California A133342: Delinquent · expires 2022-04-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-04-03
- NPI last updated
- 2021-11-18
- NPI record certified
- 2021-11-18
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.